Leiden based ProQR invented the idea of using RNA oligonucleotides to induce ADAR to edit RNA over 10 years ago - the first programs are scheduled to enter the clinic soon

Oct 8, 2024
1 min read

Founder and CEO Daniel de Boer describes ProQR's history in Leiden and why it is an ideal spot for a biotech company to be based. Plus, he walks us through the company's RNA editing approach and updates us on the status of its programs, two of which are guided to enter the clinic in late 2024/early 2025.

https://vimeo.com/1017465003

Recent Posts

See All

$BIO 2026: The gout market is currently served by two extremes, generic allopurinol in first line and a therapy for extreme refractory cases. Crystalys' experienced team wants to change that$

BIO 2026: The gout market is currently served by two extremes, generic allopurinol in first line and a therapy for extreme refractory cases. Crystalys' experienced team wants to change that

BIO 2026: Rakuten Medical's drug-device 'photoimmunotherapy' is already approved in Japan for head & neck cancer - it is currently in a global phase 3 with an eye on a U.S. approval

BIO 2026: After presenting updated data at both ASH and EHA, Paris based Enterome is hoping to start a phase 3 for its multi-target peptide immunotherapy in follicular lymphoma

Leiden based ProQR invented the idea of using RNA oligonucleotides to induce ADAR to edit RNA over 10 years ago - the first programs are scheduled to enter the clinic soon

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight